McKesson (NYSE:MCK) announced its earnings results on Thursday, October 25th. The company reported $3.60 EPS for the quarter, topping the Zacks’ consensus estimate of $3.28 by $0.32, Fidelity Earnings reports. The firm had revenue of $53.08 billion during the quarter, compared to analysts’ expectations of $53.56 billion. McKesson had a return on equity of 26.55% and a net margin of 0.06%. McKesson updated its FY 2019 guidance to $13.20-13.80 EPS.
NYSE MCK traded down $1.76 on Friday, reaching $130.81. 805,179 shares of the stock traded hands, compared to its average volume of 1,715,922. The company has a quick ratio of 0.56, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The firm has a market cap of $25.93 billion, a PE ratio of 10.37, a price-to-earnings-growth ratio of 1.51 and a beta of 1.05. McKesson has a 12 month low of $117.19 and a 12 month high of $178.86.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 2nd. Shareholders of record on Monday, December 3rd will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Friday, November 30th. McKesson’s dividend payout ratio (DPR) is presently 12.36%.
A number of research firms recently issued reports on MCK. Jefferies Financial Group restated a “buy” rating and set a $160.00 price objective on shares of McKesson in a report on Friday, July 27th. Robert W. Baird cut McKesson from an “outperform” rating to a “neutral” rating in a report on Friday, July 20th. Citigroup dropped their price objective on McKesson from $160.00 to $2.86 and set a “buy” rating for the company in a report on Friday, July 20th. Mizuho restated a “hold” rating and set a $133.00 price objective on shares of McKesson in a report on Sunday, August 12th. Finally, ValuEngine upgraded McKesson from a “strong sell” rating to a “sell” rating in a report on Monday, October 29th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $150.26.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.